Alemtuzumab
- Generic Name
- Alemtuzumab
- Brand Names
- Campath, Lemtrada, MabCampath
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216503-57-0
- Unique Ingredient Identifier
- 3A189DH42V
- Background
Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regio...
- Indication
用于烷化剂氟达拉滨（fludarabine）治疗失败的B细胞性慢性淋巴细胞白血病患者；亦可用于复发缓解型多发性硬化症治疗。
- Associated Conditions
- B-Cell Chronic Lymphocytic Leukemia, Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Steroid Refractory Acute Graft Versus Host Disease, T-cell Prolymphocytic Leukemia (T-PLL), Refractory Autoimmune Hemolytic Anemia, Refractory Idiopathic thrombocytopenic purpura
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 27
- Registration Number
- NCT04232085
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Autologous Transplant Targeted Against Crohn's
- Conditions
- Interventions
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT04154735
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Emory University
- Target Recruit Count
- 43
- Registration Number
- NCT04018937
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Phoenix Children's, Phoenix, Arizona, United States
🇺🇸Yale University, Yale Cancer Center, New Haven, Connecticut, United States
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT03989466
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
- Conditions
- Interventions
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2024-10-30
- Target Recruit Count
- 30
- Registration Number
- NCT03910452
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 242
- Registration Number
- NCT03821610
- Locations
- 🇬🇧
Cardiff and Vale University Health Board, Cardiff, United Kingdom
🇬🇧The Clatterbridge Cancer Centre Nhs Foundation Trust, Liverpool, United Kingdom
🇬🇧University Hospitals of Leicester Nhs Trust, Leicester, United Kingdom
Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment
- Conditions
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 17
- Registration Number
- NCT03806387
- Locations
- 🇩🇰
Aarhus University, Health, Section for Sport Science, Aarhus, Jutland, Denmark
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Paul Szabolcs
- Target Recruit Count
- 5
- Registration Number
- NCT03653338
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Paul Szabolcs
- Target Recruit Count
- 8
- Registration Number
- NCT03630211
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
- Conditions
- Interventions
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 48
- Registration Number
- NCT03579875
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.